India, June 22 -- Praxis Precision Medicines, Inc. (PRAX) rose in trading after the U.S. FDA granted Breakthrough Therapy Designation to Elsunersen for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE). The designation follows encouraging early clinical results and is expected to accelerate the therapy's development timeline.
SCN2A-DEE is a rare and severe pediatric neurological disorder marked by early-onset, difficult-to-control seizures. Current treatment options are limited, and many children experience significant developmental impairment.
Clinical Data Supporting the FDA Decision
The FDA's decision was based on findings from Part A of the EMBRAVE study, which evaluated Elsunersen...